Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
DAWN 
Day One Biopharmaceuticals Inc (DAWN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/05/2025: DAWN (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $23.78
1 Year Target Price $23.78
| 4 | Strong Buy |
| 3 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -52.5% | Avg. Invested days 19 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/05/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 938.45M USD | Price to earnings Ratio - | 1Y Target Price 23.78 |
Price to earnings Ratio - | 1Y Target Price 23.78 | ||
Volume (30-day avg) 8 | Beta -1.25 | 52 Weeks Range 5.63 - 16.76 | Updated Date 11/6/2025 |
52 Weeks Range 5.63 - 16.76 | Updated Date 11/6/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.52 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date 2025-11-10 | When - | Estimate -0.2929 | Actual -0.19 |
Profitability
Profit Margin -113.53% | Operating Margin (TTM) -60.94% |
Management Effectiveness
Return on Assets (TTM) -18.58% | Return on Equity (TTM) -30.16% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 310969262 | Price to Sales(TTM) 7.02 |
Enterprise Value 310969262 | Price to Sales(TTM) 7.02 | ||
Enterprise Value to Revenue 1.66 | Enterprise Value to EBITDA -7.18 | Shares Outstanding 102675502 | Shares Floating 78910230 |
Shares Outstanding 102675502 | Shares Floating 78910230 | ||
Percent Insiders 16.94 | Percent Institutions 86.2 |
Upturn AI SWOT
Day One Biopharmaceuticals Inc
Company Overview
History and Background
Day One Biopharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for childhood cancers. Founded in 2018, the company focuses on addressing unmet needs in pediatric oncology through innovative drug development.
Core Business Areas
- Oncology Drug Development: Focuses on discovering, developing, and commercializing therapies for pediatric cancers.
Leadership and Structure
The leadership team consists of experienced professionals in oncology drug development and commercialization. The organizational structure is designed to support research, clinical development, and potential commercial activities.
Top Products and Market Share
Key Offerings
- Tovorafenib (DAY101): Tovorafenib is Day One's lead product candidate, a highly selective oral brain-penetrant RAF kinase inhibitor being developed for relapsed or progressive pediatric low-grade glioma (pLGG). It is currently in Phase 3 clinical trials. Competitors include drugs that treat symptoms from LGG and other investigational therapies in development.
Market Dynamics
Industry Overview
The biopharmaceutical industry focusing on oncology is characterized by high growth, intense competition, and significant R&D investment. There's an increasing focus on precision medicine and targeted therapies, especially for rare cancers like those affecting children.
Positioning
Day One Biopharmaceuticals is positioned as a leader in developing targeted therapies for pediatric cancers, particularly pLGG. Their competitive advantage lies in their focus on this niche and the potential of Tovorafenib.
Total Addressable Market (TAM)
The global pediatric cancer therapeutics market is estimated to be worth billions of dollars. Day One's focus on pLGG allows them to address a significant unmet need within this larger market.
Upturn SWOT Analysis
Strengths
- Targeted therapy focus
- Strong pipeline candidate (Tovorafenib)
- Experienced management team
- Focus on high unmet need
Weaknesses
- Single product pipeline dependence
- Clinical trial risks
- Regulatory approval hurdles
- Limited commercial infrastructure
Opportunities
- Expanding indications for Tovorafenib
- Potential partnerships with larger pharmaceutical companies
- Acquisition or licensing of new pipeline assets
- Positive clinical trial results for Tovorafenib
Threats
- Competition from other oncology drugs
- Unfavorable clinical trial outcomes
- Changes in regulatory landscape
- Pricing and reimbursement pressures
Competitors and Market Share
Key Competitors
- MRTX
- NKTR
- ZYME
Competitive Landscape
Day One competes with other pharmaceutical companies developing oncology drugs. The competitive landscape is intense, with numerous companies vying for market share.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is primarily reflected in the advancement of Tovorafenib through clinical trials and securing funding for operations.
Future Projections: Future growth depends heavily on the successful completion of clinical trials and regulatory approval of Tovorafenib. Analyst estimates would be based on these factors.
Recent Initiatives: Recent initiatives include advancing Tovorafenib into Phase 3 clinical trials and expanding the development program to include other indications.
Summary
Day One Biopharmaceuticals is a clinical-stage company with a promising lead product candidate in Tovorafenib, targeting a significant unmet need in pediatric low-grade glioma. The company's success hinges on positive clinical trial results and regulatory approval. Dependence on a single product and clinical trial risks are key considerations. The company is poised for growth if Tovorafenib is successfully commercialized.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Day One Biopharmaceuticals Inc
Exchange NASDAQ | Headquaters Brisbane, CA, United States | ||
IPO Launch date 2021-05-27 | CEO, President & Director Dr. Jeremy Bender M.B.A., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 184 | Website https://dayonebio.com |
Full time employees 184 | Website https://dayonebio.com | ||
Day One Biopharmaceuticals, Inc., a commercial-stage company, focused on advancing class medicines for childhood and adult diseases with equal intensity in the United States. The company's lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed or refractory low-grade glioma; and Ipsen, a frontline raf-altered pLGG which is in Phase III clinical trial stage. It also developing DAY301, which is in phase I clinical trial for adult and pediatric cancers; and VRK1 Inhibitor which is in pre-clinical stage for adult and pediatric cancers. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.